Wedbush Upgrades Cidara Therapeutics (CDTX) to Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil jumps 2%, settles at 6-month highs on fears of escalation in Iran
Tweet
Share
E-mailGet Alerts CDTX Hot Sheet
Price: $221.38 --0%
Rating Summary:
13 Buy, 6 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 16 | New: 13
Rating Summary:
13 Buy, 6 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 16 | New: 13
Join SI Premium – FREE
Wedbush analyst Robert Driscoll upgraded Cidara Therapeutics (NASDAQ: CDTX) from Neutral to Outperform with a price target of $4.00 (from $2.00).
For an analyst ratings summary and ratings history on Cidara Therapeutics click here. For more ratings news on Cidara Therapeutics click here.
Shares of Cidara Therapeutics closed at $2.35 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Evercore ISI Upgrades Clorox (CLX) to In Line
- New Street Research Upgrades Telia Co AB (TELIA:SS) (TLSNF) to Buy
- Kilroy Realty (KRC) PT Lowered to $36 at Wells Fargo
Create E-mail Alert Related Categories
Analyst PT Change, UpgradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
